Synthesis and biological activity of a novel class of small molecular weight peptidomimetic competitive inhibitors of protein tyrosine phosphatase 1B

Journal of Medicinal Chemistry

Volumn 45, Issue 3, 2002, Pages 598-622

  Larsen, Scott D ^a   Barf, Tjeerd ^b   Liljebris, Charlotta ^b   May, Paul D ^a   Ogg, Derek ^c   O'Sullivan, Theresa J ^a   Palazuk, Barbara J ^a   Schostarez, Heinrich J ^a   Stevens, F Craig ^a   Bleasdale, John E ^a  

^a PFIZER INC   (United States)

^b Biovitrum AB ^*  (Sweden)

^c BIOVITRUM AB   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

2 (CARBOXYMETHOXY) 5 [2 [[2 [(3 CARBOXYPROPANOYL)AMINO] 3 PHENYLPROPANOYL]AMINO] 3 OXO 3 (PENTYLAMINO)PROPYL]BENZOIC ACID; 4 NITROPHENYL PHOSPHATE; 5 [2 [[2 [(TERT BUTOXYCARBONYL)AMINO] 3 PHENYLPROPANYL]AMINO] 3 OXO 3 (PENTYLAMINO)PROPYL] 2 (CARBOXYMETHOXY)BENZOIC ACID; ANTIDIABETIC AGENT; ASPARTIC ACID; CARBOXYLIC ACID; DEOXYGLUCOSE; INSULIN; INSULIN RECEPTOR; METHYL 5 [2 [[2 [(4 METHOXY 4 OXOBUTANOYL)AMINO] 3 PHENYLPROPANOYL]AMINO] 3 OXO 3 (PENTYLAMINO)PROPYL] 2 (2 METHOXY 2 OXOETHOXY)BENZOATE; PHENYLALANINE; PHOSPHATE; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE PHOSPHATASE 1B; PROTEIN TYROSINE PHOSPHATASE INHIBITOR; SALICYLIC ACID DERIVATIVE; TRIPEPTIDE; TYROSINE; TYROSINE SULFATE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG ACTIVITY; DRUG SYNTHESIS; ENZYME ACTIVITY; ENZYME INHIBITION; INSULIN RESISTANCE; MOLECULAR WEIGHT; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PROTEIN PHOSPHORYLATION; RAT; X RAY CRYSTALLOGRAPHY;

CELL LINE; CRYSTALLOGRAPHY, X-RAY; DEOXYGLUCOSE; DIPEPTIDES; ENZYME INHIBITORS; HYDROGEN BONDING; INSULIN; MODELS, MOLECULAR; MOLECULAR MIMICRY; MOLECULAR WEIGHT; PEPTIDES; PROTEIN-TYROSINE-PHOSPHATASE; STRUCTURE-ACTIVITY RELATIONSHIP; TYROSINE;

EID: 0037204009     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm010393s     Document Type: Article

References (50)

1. The syndrome of insulin resistance
2. Insulin resistance or insulin deficiency? Which is the primary cause of NIDDM?
3. Role of insulin resistance in the pathophysiology of noninsulin dependent diabetes mellitus
4. The insulin signaling system
5. Diverse signaling pathways in the cellular actions of insulin
6. Insulin action, diabetogenes, and the cause of type II diabetes
7. Protein tyrosine phosphatase 1B interacts with the activated insulin receptor
8. Analysis of in vitro interactions of protein tyrosine phosphatase 1B with insulin receptors
9. Protein-Tyrosine Phosphatase 1B complexes with the insulin receptor in vivo and is tyrosine-phosphorylated in the presence of insulin
10. Sequential dephosphorylation of a multiply phosphorylated insulin receptor peptide by protein tyrosine phosphatases
11. Osmotic loading of neutralizing antibodies demonstrates a role for Protein-Tyrosine Phosphatase 1B in negative regulation of the insulin action pathway
12. Protein-tyrosine Phosphatase 1B Is a negative regulator of insulin- and insulin-like growth factor-I-stimulated signaling
13. Alterations in skeletal muscle protein-tyrosine phosphatase activity and expression in insulin-resistant human obesity and diabetes
14. Improved sensitivity to insulin in obese subjects following weight loss is accompanied by reduced protein-tyrosine phosphatases in adipose tissue
15. A phosphotyrosyl mimetic peptide reverses impairment of insulin-stimulated translocation of GLUT4 caused by overexpression of PTP1B in rat adipose cells
16. Thiazolidine derivatives ameliorate high glucose-induced insulin resistance via the normalization of Protein-Tyrosine Phosphatase activities
17. Increased insulin sensitivity and obesity resistance in mice lacking the Protein Tyrosine Phosphatase-1B gene
18. Mechanism of inhibition of Protein-Tyrosine Phosphatases by Vanadate and Pervanadate
19. Selective inactivation of protein tyrosine phosphatase PTP1B by sulfone analogue of naphthoquinone
20. Examination of novel non-phosphorus-containing phosphotyrosyl mimetics against Protein Tyrosine Phosphatase-1B and demonstration of differential affinities toward Grb2 SH2 domains
21. Structure-based design of a low molecular weight, nonphosphorus, nonpeptide, and highly selective inhibitor of Protein-tyrosine Phosphatase 1B
22. Preparation of chiral α-monofluoroalkylphosphonic acids and their evaluation as inhibitors of protein tyrosine phosphatase 1B
23. Synthesis and characterization of a novel class of protein tyrosine phosphatase inhibitors
24. Novel benzofuran and benzothiophene biphenyls as inhibitors of protein tyrosine phosphatase 1B with antihyperglycemic properties
25. New azolidinediones as inhibitors of protein tyrosine phosphatase 1B with antihyperglycemic properties
26. Synthesis and biological evaluation of α,α-difluorobenzylphosphonic acid derivatives as small molecular inhibitors of protein-tyrosine phosphatase 1B
27. Potent and highly selective inhibitors of the protein tyrosine phosphatase 1B
28. PTP1B inhibition and antihyperglycemic activity in th ob/ob mouse model of novel 11-arylbenzo[b]naphtho[2,3-d]furans and 11-arylbenzo[b]naphtho-[2,3-d]thiophenes
29. Protein tyrosine phosphatases: Structure, mechanism, and inhibitor discovery
30. Protein tyrosine phosphatase substrate specificity: Size and phosphotyrosine positioning requirements in peptide substrates
31. Small molecule peptidomimetics containing a novel phosphotyrosine bioisostere inhibit Protein Tyrosine Phosphatase 1B (PTP1B) and augment insulin action
32. Inhibition of protein tyrosine phosphatase PTP1B and CD45 by sulfotyrosyl peptides
33. L-O-(2-Malonyl)tyrosine: A new phosphotyrosyl mimetic for the preparation of Src homology 2 domain inhibitory peptides
34. Disproportionation in aryloxymalonic acid syntheses
35. Stereocontrolled synthesis of hydroxymethylene phosphonate analogues of phosphorylated tyrosine and their conversion to monofluoromethylene phosphonate analogues
36. A palladium-catalyzed carbonylative route to primary amides
37. EPSP synthase inhibitor design II. The importance of the 3-phosphate group for ligand binding at the shikimate-3-phosphate site and the identification of 3-malonate ethers as novel 3-phosphate mimics
38. Protein-tyrosine phosphatase inhibition by a peptide containing the phosphotyrosyl mimetic, L-O-malonyltyrosine
39. Structural basis for phosphotyrosine peptide recognition by protein tyrosine phosphatase 1B
40. Enantioselective synthesis of nonphosphorus-containing phosphotyrosyl mimetics and their use in the preparation of tyrosine phosphatase inhibitory peptides
41. 2-(Oxalylamino)-benzoic acid is a general, competitive inhibitor of protein-tyrosine phosphatases
42. Determinants of substrate recognition in the protein-tyrosine phosphatase, PTP1
43. Quantitative approaches to delineate paracellular diffusion in cultured epithelial cell monolayers
44. Tyrosine-modified analogues of methionine-enkephalin and their effects on the mouse vas deferens
45. Molecular basis for substrate specificity of Protein-Tyrosine Phosphatase 1B
46. Structural basis of plasticity in Protein Tyrosine Phosphatase 1B substrate recognition
47. Practical enantioselective synthesis of a homotyrosine derivative and (R,R)-4-propyl-9-hydroxynaphthoxazine, a potent dopamine agonist
48. Expression of a dominant negative SHP-2 in transgenic mice induces insulin resistance
49. Combinatorial control of the specificity of protein tyrosine phosphatases